Rapid Therapeutic Science Laboratories (Rapid Therapeutic Science Laboratories) Cash per Share : $0.00 (As of Jun. 2023)

View and export this data going back to 2013. Start your Free Trial

What is Rapid Therapeutic Science Laboratories Cash per Share?

Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities divided by Shares Outstanding (EOP). Rapid Therapeutic Science Laboratories's Cash per Share for the quarter that ended in Jun. 2023 was $0.00.

Rapid Therapeutic Science Laboratories Cash per Share Historical Data

The historical data trend for Rapid Therapeutic Science Laboratories's Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rapid Therapeutic Science Laboratories Cash per Share Chart

Rapid Therapeutic Science Laboratories Annual Data

Trend

Mar13

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Dec21

Dec22

Cash per Share

Get a 7-Day Free Trial

0.25

0.02

0.03

Rapid Therapeutic Science Laboratories Quarterly Data
	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23
Cash per Share	Get a 7-Day Free Trial															0.01	-	-	-	-

Rapid Therapeutic Science Laboratories Cash per Share Calculation

This is the ratio of a company's available cash, including easy to liquidate short-term investment, to its total number of shares outstanding. The result indicates the percentage of a company's share price that is available to spend on company's activities, such as strengthening the business, paying down the debt and making dividend payment to shareholders. It's a reliable indicator of a company's financial health.

Rapid Therapeutic Science Laboratories's Cash per Share for the fiscal year that ended in Dec. 2022 is calculated as:

Cash per Share	=	Cash, Cash Equivalents, Marketable Securities	/	Shares Outstanding (EOP)
	=	0	/	7.76
	=	0.00

Rapid Therapeutic Science Laboratories's Cash per Share for the quarter that ended in Jun. 2023 is calculated as:

Cash per Share	=	Cash, Cash Equivalents, Marketable Securities	/	Shares Outstanding (EOP)
	=	0.002	/	8.83
	=	0.00

Rapid Therapeutic Science Laboratories (OTCPK:RTSL) Cash per Share Explanation

Cash per Share represents the liquidity of a compant's assets. A high level of Cash per Share suggests that there's enough money on hand for a company to cover any emergencies and that the company has adequate money to reinvest its business or pay dividends to investors. However, if the ratio is too high, it can also suggeust the inefficiency of management for not making a full usage of the cash.

Rapid Therapeutic Science Laboratories Cash per Share Related Terms

Thank you for viewing the detailed overview of Rapid Therapeutic Science Laboratories's Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Rapid Therapeutic Science Laboratories (Rapid Therapeutic Science Laboratories) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Rapid Therapeutic Science Laboratories Inc (OTCPK:RTSL) » Definitions » Cash per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

5580 Peterson Lane, Suite 120, Dallas, TX, USA, 75201

Website

https://www.rtslco.com

Rapid Therapeutic Science Laboratories Inc is a biotech company specializing in natural-based relief through aerosol delivery of cannabinoids to the systemic bloodstream through the pulmonary route of administration. The company manufactures its own branded metered dose inhalers (MDI) under the nhaler name using proprietary blends of pure cannabinoids such as cannabidiol (CBD) and cannabigerol (CBG). In addition, the company manufactures other aerosol devices for the delivery of cannabinoids other than MDI such as sublingual sprays.

Executives

Henry Anthony Punzi	director	1932 WALNUT PLAZA, CARROLLTON TX 75006
Scott Suggs Justin	director	639 SWORD BRIDGE DR., LEWISVILLE TX 75056
Sean Paul Berrier	10 percent owner	7108 DUFFIELD DR., DALLAS TX 75248
Schmidt Donal Ray Jr.	director, 10 percent owner, officer: President and CEO	5580 PETERSON LANE, SUITE 200, DALLAS TX 75240
Ryan Casey Johnson	director, officer: Chief Operating Officer	2307 CASTLE ROCK RD, CARROLTON TX 75007
Texas Mdi, Inc.	10 percent owner	5580 PETERSON LANE, SUITE 200, DALLAS TX 75240
D Hughes Watler	director, officer: CFO	2323 S. VOSS ROAD, STE. 510-12, HOUSTON TX 77057
Steve Bond	director, officer: CFO	28839 PUJOL ST., #832, TEMECULA CA 92590
Brent Willson	director, officer: CEO and President	5271 CAMINITO EXQUISITO, SAN DIEGO CA 92130